At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
Testosterone Cypionate 100 MG/ML +1 moredrug
Likely dose
Testosterone Cypionate 100 MG/MLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
In Brief
A Phase 2 clinical trial evaluating Testosterone Cypionate 100 MG/ML and Placebo for Prostate Cancer. Completed, enrolled 136 participants across 3 sites.
Detailed Summary
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartMar 2019
Primary CompletionMay 2025
Study CompletionJul 2025
TodayJul 2026
First PostedOct 23, 2018
Enrollment StartMar 19, 2019
Primary CompletionMay 16, 2025
Study CompletionJul 16, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.7 years ago
Interventions
Testosterone Cypionate 100 MG/MLdrug
100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
Placebodrug
Placebo administered by intramuscular injection weekly for 12 weeks.